Westhovens, R
Taylor, P C
Alten, R
Pavlova, D
Enríquez-Sosa, F
Mazur, M
Greenwald, M
Van der Aa, A
Vanhoutte, F
Tasset, C
Harrison, P
Clinical trials referenced in this document:
Documents that mention this clinical trial
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
https://doi.org/10.1136/annrheumdis-2016-210104
POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE
https://doi.org/10.1136/annrheumdis-2023-eular.3508
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study
https://doi.org/10.1136/rmdopen-2024-004857
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes
https://doi.org/10.1136/rmdopen-2024-005033
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
This article is maintained by: Elsevier
Article Title: Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2016-210104
CrossRef DOI link to the associated document: https://doi.org/10.1136/annrheumdis-2016-210105
Content Type: article
Copyright: Copyright © 2016 Published by Elsevier Inc. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.